ArticleJAC-antimicrobial resistance2025
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ceftazidime/avibactam has been introduced as a promising treatment option against multidrug-resistant Gram-negative bacteria. Objectives: To investigate the development of ceftazidime/avibactam resistance in a Methods: Eight clinical isolates were recovered from a single patient treated with ceftazidime/avibactam. The isolates were analysed using antimicrobial susceptibility testing, and WGS to identify potential resistance mechanisms. Results: Ceftazidime/avibactam resistance emerged during treatment, accompanied by significant increases in aztreonam/avibactam and avibactam MICs. All isolates, including those susceptible to ceftazidime/avibactam, had a YRIK insertion in PBP3. Additional mutations were identified in the AcrB efflux pump component and, in most cases in its regulatory genes and PBP2 in the resistant isolates. No significant differences in Conclusions: This study shows a complex resistance mechanism involving a YRIK insertion in PBP3, combined with mutations in AcrB and PBP2, as drivers of ceftazidime/avibactam resistance. These findings highlight the importance of monitoring
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.